National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 2) (PB 25 of 2018) (Cth)

PB 25 of 2018

National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 2)

National Health Act 1953

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated      26    March 2018

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2018 (No. 2).

(2)   This Determination may also be cited as PB 25 of 2018.

1. Commencement

This Determination commences on 1 April 2018.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Artemether with lumefantrine

Omit

Atazanavir

Asenapine

Insert

Asenapine

Atazanavir

Atezolizumab

[2]     Schedule 1, after item dealing with Ceritinib

Omit

Certolizumab pegol

[3]     Schedule 1, after item dealing with Fusidic acid

Omit

Ganciclovir

[4]     Schedule 1, after item dealing with Posaconazole

Insert

Pralatrexate

[5]     Schedule 1, after item dealing with Sofosbuvir

Insert

Sonidegib

[6]     Schedule 1, after item dealing with Travoprost

Omit

Trifluoperazine

[7]     Schedule 2, after item dealing with Bromocriptine

Insert

Budesonide with eformoterol

[8]     Schedule 2, after item dealing with Cephazolin

Insert

Certolizumab pegol

[9]     Schedule 2, after item dealing with Galantamine

Insert

Ganciclovir